key: cord-0730943-tvp6i66g
authors: Sahin Tutak, Ayse; Söylemez, Fatih; Konuk, Hazal B.; Çakmak, Erkan; Karakaya, Bülent; Doğan, Ali; Sayiner, Hakan S.; Aksöz, Selçuk; Alev, Mehtap
title: A Patient Presenting with ARDS After COVID-19 Vaccination: A COVID-19 Case Report
date: 2021-06-02
journal: J Infect Public Health
DOI: 10.1016/j.jiph.2021.05.017
sha: 3fab427d0a00947c39d03767da1543100a7debf0
doc_id: 730943
cord_uid: tvp6i66g

COVID-19 is a disease caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). The introduction of vaccines against COVID-19 caused great enthusiasm around the world as immunization might end the pandemic. However, it was previously stated that COVID-19 cases would rarely continue to occur despite immunization. Fourteen days after the second dose of the vaccine, a 66-year-old male patient with a negative COVID-19 PCR test result and high levels of IgG and low levels of IgM-A against SARS-CoV-2 was admitted to our intensive care unit (ICU) due to the clinical picture of Acute Respiratory Distress Syndrome (ARDS). We aimed to stress the need for continuing preventive measures in vaccinated individuals, too, by presenting the clinical findings of the patient, who was considered to have developed ARDS due to COVID-19, as high levels of IgG and IgM-A against SARS-CoV-2 were detected on day 8 during ICU admission.

COVID-19 is a disease caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2). The incubation period of the disease varies from 2 to 14 days (median 5 days).

Although the disease is asymptomatic in some patients, it may progress to pneumonia, respiratory failure, and even death at the end of the first week in some cases. (1) Since vaccines against COVID-19 have become available in recent months, it is too early to know the length of the protection period against COVID-19 after vaccination. Studies are ongoing to answer this question. Even though the available data are encouraging by showing that most survivors of COVID-19 have developed an immune response that enabled protection against reinfection for at least some time, the efficacy and the length of such protection and protective levels of SARS-CoV-2 IgG antibodies still need to be established.

In this study, we aimed to present the clinical findings of a patient, who was treated for acute respiratory distress syndrome (ARDS) in the intensive care unit (ICU) despite the presence of high levels of SARS-CoV-2 IgG antibodies developing after vaccination, and thus, to stress the need for continuing preventive measures.

J o u r n a l P r e -p r o o f Case Report:

A 66-year-old male patient was admitted to the emergency department with shortness of breath. The medical history of the patient informed that he had had fatigue for three days and developed shortness of breath a day ago. The patient was dyspneic and hypoxic and had oxygen saturation levels ranging from 85 to 90 under oxygen therapy that was administered at a rate of 15-20lt/min through a nasal cannula and an oxygen reservoir bag in the emergency department. The result of the PCR test for COVID -19 was negative(It has been worked on the PCR ROCHE BİO-RAD Kiagen device, RTA kit). In the thoracic CT sections, the patient had ground-glass densities diffusely. On the posterior-anterior chest X-ray (PA-CXR), diffuse infiltration was observed bilaterally (Figure 1 -a, c, d). The patient was admitted to ICU due to the diagnosis of COVID-19 pneumonia. The patient had received the second dose of the COVID-19 vaccine 14 days ago. The patient did not have comorbidity. Despite the administration of a combination of high-flow oxygen (HFO) therapy and delivery of oxygen via a reservoir mask (RMO), non-invasive CPAP treatment was initiated when the oxygen saturation levels of the patient dropped to levels of 78-80. Despite the treatment, the patient with a respiratory rate of >30 and a PaO2/FiO2 ratio of ≤100 (PEEP ≥5 cmH20) was considered to have severe ARDS and was intubated electively on the first day of admission.There was no reproduction ETA cultures .Tested Adenovirüs, influenza, parainfluenza, respiratory sinsityalvirüs,mycoplasma and leigonella negative. In addition to broad-spectrum antibiotherapy (Ceftriaxone and levofloxacin were added to the treatment while the patient was admitted to the ICU. Antibiotics were stopped at the 48th hour of hospitalization due to the lack of growth in the cultures and poor general condition, and the treatment was changed to vancomycin + imipenem. Colimicin was added to the treatment when acinetobacter growth occurred in sputum culture), methylprednisolone therapy was started at a dose of 250 mg/day. Favipiravir, low molecular weight heparin (LMWH), and high-dose ascorbic acid intravenously were added to the treatment because of the suspicion of COVID-19 causing ARDS. The patient had high procalcitonin levels, therefore, he was not considered suitable for receiving tocilizumab therapy. The PCR test for COVID-19 on the endotracheal aspiration fluid, which was collected after intubating the patient, was reported as negative. The antibody tests using theELISA method (ELISA GRİFOLS branded TİRİTÜRÜS model has been studied) at the time of the second PCR test showed SARS-Cov-2 IgG and IgM-A levels of 30.5 (≥6) and 6.17 (≥8), respectively. The patient was placed J o u r n a l P r e -p r o o f in the prone and supine positions alternately. Saturation levels measured every 12-16 hours showed a decreasing trend. PA-CXR findings progressed in time (Figure 1-b) . The repeated COVID-19 PCR test on day 8 of hospitalization was negative and the levels of IgG and IgM-A to SARS-CoV-2 were 48.80 (≥6) and 14 (8), respectively (Table-1 ). The patient died on day 9 of hospitalization. theCOVID-19 vaccines in use have been shown to be highly effective, the efficacy of none of them will be 100%. After receiving a single dose of vaccine, immunity will usually develop after two weeks following vaccination. In double-dose vaccination regimens, the administration of both doses is necessary to achieve optimum immunization. It is estimated that vaccines against COVID-19 will enable immunization at least to a certain extent against new virus variants and be effective in preventing severe cases and death.

The imaging test findings ( Figure 1) 

Our patient was admitted to ICU on day 14 after receiving the second dose of the vaccine, due to the diagnosis of severe ARDS (PaO2/FiO2 ≤ 100) (5) and underwent elective intubation.

At the time of ICU admission, the patient's IgG level to SARS-CoV-2 was high and IgM-A level was low (Table 1) . On day 8 of ICU admission, his IgM-A level increased confirming the definite diagnosis of ARDS due to active COVID-19. In a study using ELISA test, SARS-CoV-2 IgG antibodies were detected in less than 60% of the samples on days 6 and 10

following the onset of the disease. (6-7) In our patient, the initial high level of IgG was associated with the vaccination.

For the patient of this case report, favipiravir with established efficacy was included in the treatment as a loading dose and maintenance doses. theCOVID-19 vaccines in use have been shown to be highly effective, the efficacy of none of them will be 100%. After receiving a single dose of vaccine, immunity will usually develop after two weeks following vaccination. In double-dose vaccination regimens, the J o u r n a l P r e -p r o o f administration of both doses is necessary to achieve optimum immunization. It is estimated that vaccines against COVID-19 will enable immunization at least to a certain extent against new virus variants and be effective in preventing severe cases and death.

The World Health Organization recommends that anyone should have access to the safe and effective COVID-19 vaccines as soon as possible, with the prioritization of those with the highest risk of severe disease and death. However, considering that our patient died of ARDS despite the high SARS-CoV-2 IgG level, we suggest that protective measures should be continued even after vaccination, until the pandemic is over.

J o u r n a l P r e -p r o o f

A Review of Coronavirus Disease-2019 (COVID-19)

False-negative results of real-time reversetranscriptase polymerase chain reaction for severe acute respiratory syndrome coronavirus 2: role of deep-learning-based CT diagnosis and insights from two cases

Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19

Combination of RT-qPCR testing and clinical features for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak

Acute respiratory distress syndrome: Clinical features and diagnosis in adults

Evaluation of nucleo capsid and spike protein-based

ELISAs for detecting antibodies against SARS-CoV-2

Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples

Discovering drugs to treat coronavirus disease

Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomized controlled trial

Effective treatment of severe COVID-19 patients with tocilizumab

Acute Respiratory Distress Syndrome